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Abstract
Caspase-6 is a cysteinyl protease implicated in neurodegenerative conditions including Alzheimer’s and Huntington’s
disease making it an attractive target for therapeutic intervention. A greater understanding of the role of caspase-6 in
disease has been hampered by a lack of suitable cellular assays capable of specifically detecting caspase-6 activity in an
intact cell environment. This is mainly due to the use of commercially available peptide substrates and inhibitors which lack
the required specificity to facilitate development of this type of assay. We report here a 384-well whole-cell
chemiluminescent ELISA assay that monitors the proteolytic degradation of endogenously expressed lamin A/C during
the early stages of caspase-dependent apoptosis. The specificity of lamin A/C proteolysis by caspase-6 was demonstrated
against recombinant caspase family members and further confirmed in genetic deletion studies. In the assay, plasma
membrane integrity remained intact as assessed by release of lactate dehydrogenase from the intracellular environment
and the exclusion of cell impermeable peptide inhibitors, despite the induction of an apoptotic state. The method described
here is a robust tool to support drug discovery efforts targeting caspase-6 and is the first reported to specifically monitor
endogenous caspase-6 activity in a cellular context.
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Introduction
Caspases are cysteine proteases that mediate a variety of
processes including regulation of the inflammatory response and
mediating programmed cell death. Various apoptotic caspases
have been shown to play a crucial role in embryonic development
and tissue homeostasis [1], while deregulation of caspase activity is
observed in a variety of pathological conditions. The role that
caspase-6 plays in various neurodegenerative conditions is the
topic of investigation by numerous groups and highlights the desire
to identify selective pharmacological reagents to disrupt enzymatic
activity. Several lines of evidence connect caspase-6 with
Alzheimer’s disease (AD) including localization in disease brains
and neurofibrillary tangles [2,3] as well as direct cleavage of
proteins with known involvement in AD progression [4,5].
Furthermore, axonal degeneration induced by APP activation of
DR6 was reported to be mediated by caspase-6 activity [6].
Caspase-6 is also thought to play a role in Huntington’s disease as
it mediates cleavage of mutant huntingtin protein to induce
pathogenesis in relevant disease models [7–9]. More recently
caspase-6 has also been implicated in Parkinson’s disease as the
neuroprotective function of DJ-1 protein is dependent on caspase-
6 proteolysis [10]. Despite the allure of caspase-6 as a therapeutic
target, however, there are no drug-like therapies that selectively
modulate this enzyme.
Caspase-6 is classified as an executioner caspase based on its
structural homology to caspase-3 and -7 and its requirement for
activation by upstream initiator caspases [11,12], although
alternative mechanisms of activation have been proposed [13].
Activated caspase-6 performs proteolytic digestion of a number of
substrates with an aspartic acid residue in the P1 position, with
P2–P4 amino acid residues conferring substrate specificity against
other caspase isoforms [14]. The preferred cleavage motif as
defined for caspase-6 is Valine-Glutamate-Isoleucine-Aspartate
(VEID) as defined by peptidic substrate mapping [15]. These
generalized consensus motifs provide utility as the basis of peptide
substrates that are frequently used to interrogate the activity of
caspase enzymes. Despite their utility in biochemical assays, there
are challenges with enzyme-substrate cross-reactivity [16,17].
Many of these peptide substrates are processed by a host of
different caspase isoforms and would preclude their use in a
cellular context where numerous caspase family members are
present [17,18]. The VEID sequence is found at amino acid
residues 227–230 in the helical rod region of the nuclear
intermediate filament protein lamin A/C. Despite enzyme-
substrate cross-reactivity, claims have been made that lamin A/
C is proteolyzed only by caspase-6 at this site [19–21]. Likewise,
many of the available peptide inhibitors have served as useful tools
to inhibit enzymatic activity but fail to exhibit selective caspase
isoform inhibition [22]. This is likely due to the high degree of
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the inhibitor P1 Asp residue that covalently modifies a conserved
catalytic cysteine residue [23]. Peptide inhibitor polarity may also
prevent their cell penetration thus precluding their utility as viable
tools to assist in the development of cellular caspase assays. It is
therefore no surprise that there are no published reports of assays
to specifically monitor inhibition of caspase-6 in a cellular context.
Several strategies have been reported to assess pan executioner
caspase activity in whole cells including the synthesis of cell
penetrant substrates that rely on novel fluorescent dyes or peptide
leader sequences to encourage cell uptake [24–27]. Another more
elaborate strategy to monitor cellular activity of a specific caspase
isoform was the utilization of split TEV technology to transiently
activate caspase-3. Cellular enzymatic activity from this system
[28], or others [29], is readily monitored via engineered FRET
reporters. To overcome the hurdles of complex cell engineering
and liabilities of possible substrate non-specificity, we developed a
whole cell ELISA assay to monitor the proteolysis of endogenously
expressed lamin A/C upon induction of the endogenous caspase
machinery by apoptosis. We demonstrate that this is a high
throughput, robust, whole cell assay for monitoring caspase-6
activity without compromising cellular membrane integrity. The
assay serves as a valuable tool for facilitating drug discovery efforts
against this important target.
Materials and Methods
Inhibitors
Ac-VEID-CHO, Ac-DEVD-CHO, Ac-IETD-CHO, z-VEID-
FMK, z-DEVD-FMK, z-VAD-FMK and Q-VD-OPh were
obtained from EMD4Biosciences (Gibbstown, NJ). z-VEID-tetra-
fluorophenoxymethyl (TFPM), z-EID-TFPM and z-ID-TFPM
were synthesized by the Discovery Chemistry Department at
Genentech, Inc. with procedures described previously [30,31]. All
inhibitor structures can be found in Figure S1.
Cell Culture
SKNAS Cells (ATCC #CRL-2137) were cultured in DMEM
medium supplemented with 10% FBS, 2 mM Glutamax I and 1%
Pen/Strep under incubator conditions of 37uCelsius, 90% relative
humidity with 5% CO2. Cells were split 1:5 twice weekly. Caspase-
6 KO and wild type mouse fibroblasts were cultured under the
same medium and conditions. All tissue culture reagents were
purchased from Invitrogen (Carlsbad, CA).
Enzymatic Caspase Activity Assays
Caspases-3, -6 and -7 were expressed in E. Coli and purified by
the Protein Chemistry Department at Genentech, Inc with
procedures similar to those previously published [32]. Biochemical
assays of caspase activity were carried out in 384-well black low-
volume assay plates (Perkin Elmer #6008260; Waltham, MA) in
12 ml reaction volumes containing enzyme, fluorogenic substrate
and inhibitor. All peptide inhibitors were serially diluted in DMSO
prior to cross dilution in assay buffer (50 mM HEPES pH 7.2,
25 mM MgSO4, 0.5 mM EGTA, 5 mM Glutathione, 0.01%
Triton X-100 containing 0.1% Bovine Gamma Globulin (BGG)).
Final DMSO concentration in the assay was 1.33%. Rhodamine-
labeled bivalent tetrapeptide substrates were obtained from
Anaspec (Fremont, CA) and used as follows: 300 pM caspase-3
reacted with 1 mM (Ac-DEVD)2 -Rh110, 1 nM caspase-6 reacted
with 5 mM (Ac-VEID)2 -Rh110, 5 pM caspase-7 reacted with
1 mM (Ac-DEVD)2 -Rh110. Enzyme and inhibitor were preincu-
bated for 15 minutes prior to the addition of substrate to initiate
the enzymatic reaction. The reaction was permitted to proceed for
40 minutes at room temperature and then read on an Envision
(Perkin Elmer) instrument using excitation/emission wavelengths
of 485/535 nm. To simplify potency analysis of peptide inhibitors
with the capacity to inhibit in a time-dependent manner, the
apparent IC50’s determined after combined 15 minutes of
preincubation and 40 minute enzyme reaction are reported.
Western Blotting for Cellular Lamin A/C
SKNAS cells were seeded in T-25 flasks (Corning; Lowell, MA)
at a density of 5x10
6 cells/flask in growth medium and allowed to
adhere overnight. The following day, staurosporine (Enzo;
Plymouth Meeting, PA) was delivered directly to medium in the
T-25 flask from a 10 mM stock in DMSO resulting in 3 mM final
concentration. Medium was aspirated after 6 hours incubation (or
indicated time) followed by addition of 250 ml lysis buffer (Cell
Signaling; Beverly, MA). Cell lysates were quantified for protein
content using a bicinchoninic acid (BCA) protein assay kit
(Thermo; Waltham, MA) and 50 mg of cellular lysate was
subjected to SDS-PAGE using 4–12% Bis-Tris gel (Invitrogen)
for 90 minutes at 125V. Transfer of protein to 0.45 mm
nitrocellulose membrane (Invitrogen) was performed using semi-
dry transfer apparatus (BioRad; Hercules, CA) for 60 minutes at
15V. Nitrocellulose membranes were blocked with Odyssey
blocking buffer (Licor; Lincoln, NE) for 1 hour at room
temperature prior to incubation with 1:1000 dilution of the
indicated primary anti-lamin antibody (rabbit polyclonal targeting
a neo-epitope on the small subunit of cleaved lamin A/C (Cell
Signaling #2035S); rabbit polyclonal targeting a neo-epitope on
the large subunit of cleaved lamin A/C (Cell Signaling #2031S);
rabbit polyclonal targeting intact lamin A/C (Cell Signaling
#2032)) or 1:5000 dilution of mouse monoclonal anti-b actin
antibody (Sigma #A5441) for 60 minutes at room temperature
with gentle rocking motion. The membrane was then washed 4
times for 5 minutes with Tris Buffered Saline containing 0.05%
Tween-20 (TBST) (Invitrogen) followed by incubation with
secondary antibody for 1 hour at room temperature. Dilutions
of 1:2500 (HRP-conjugated donkey anti-rabbit IgG (GE Health-
care #NA934V; Piscataway, NJ)), 1:10000 (IRDye 800 conjugat-
ed affinity purified anti-mouse IgG (Rockland, Gilbertsville, PA))
and 1:2000 (Alexa Fluor 680 goat anti-rabbit IgG (Invitrogen,
Carlsbad, CA)) were used. Finally, the membrane was washed 4
times for 5 minutes in TBST and scanned using a LiCor Odyssey
Infrared Scanning instrument (LiCor; Lincoln, NE).
Cell-based ELISA for Cleaved Lamin
SKNAS or mouse fibroblast (wild type and caspase-6 KO) cells
were plated at a density of 20,000 cells per well into poly-D-lysine
coated 384-well black clear-bottom cell culture plates (Becton
Dickinson #35-4663; Franklin Lakes, NJ) in growth medium and
allowed to adhere overnight. The following day, cell culture
medium was aspirated and replaced with 20 ml/well basal medium
(DMEM with no supplements added). All peptide inhibitors were
serially diluted in DMSO prior to cross dilution in basal medium.
5 ml of diluted inhibitor was delivered to each well and incubated
for 30 minutes in a cell culture incubator prior to addition of 5 ml/
well staurosporine in basal medium. The final DMSO concentra-
tion in the assay was 0.1% and the final staurosporine
concentration was 3 mM (or indicated concentration). Following
6 hours incubation with staurosporine, 10 ml of 16% paraformal-
dehyde (Alfa Aesar #43368; Ward Hill, MA) was added directly to
each well and incubated at room temperature for 15 minutes
before careful aspiration of each well and two 100 ml washes with
Phosphate Buffered Saline (PBS) (Invitrogen). Cells were permea-
bilized by the addition of 50 ml 0.2% Triton X-100 in PBS for
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twice with 100 ml PBS, and nonspecific binding sites blocked with
100 ml blocking agent (Thermo #37535) for 10 minutes at room
temperature. The blocking agent was replaced with 20 ml/well
rabbit polyclonal primary antibody (Cell Signaling #2035S)
delivered at 1:200 dilution in blocking agent and incubated
overnight at 4uCelsius. The following day, primary antibody was
aspirated and the wells washed 3 times with 100 ml TBST.
Secondary antibody (donkey anti-rabbit IgG, HRP-conjugated
(GE Healthcare #NA934V)) was delivered at 1:2500 dilution in
blocking agent (20 ml/well) and incubated 1 hour at room
temperature. Following aspiration, the plate was washed 5 times
with 100 ml/well TBST, chemiluminescent HRP substrate
(Thermo #37074) was added and luminescence measured
5 minutes later using a Perkin Elmer Envision instrument.
In vitro Lamin A cleavage assay
Active human recombinant caspase-6 was provided by the
Protein Chemistry Department at Genentech, Inc. All other active
caspases were purchased from Enzo LifeSciences (Cat # BML-
AK010) and used at a final concentration of 5 U/ml (300U total;
see manufacturer’s guide for description). In each assay,
recombinant glutathione S-transferase (GST)-tagged lamin A
(17 mg/ml, 170 nM) (Abnova Cat# H00004000-P01; Taipei City,
Taiwan) was incubated with active caspase enzyme at 37uC for
2 hours in assay buffer (50 mM HEPES (pH 7.5), 100 mM NaCl,
1 mM EDTA, 0.5% CHAPS, 10 mM DTT). For caspase-9, the
assay buffer was: 50 mM HEPES (pH 7.5), 100 mM NaCl, 0.01%
CHAPS, 0.5 M NaCitrate, 1 mM EDTA, 10 mM DTT. Samples
were incubated at 100uC. for 5 minutes, resolved by SDS-PAGE
(12% Tris-glycine, Invitrogen) and transferred to a nitrocellulose
membrane. The blot was probed with horseradish peroxidase
(HRP)-conjugated anti-GST antibody (1:1000) (Sigma-Aldrich; St.
Louis, MO). The signal was developed with Chemi-IR
TM
detection kit using IRDye 800CW rabbit anti-HRP antibody
(1:1000) (Licor) according to manufacturer’s recommendation. The
membrane was scanned on a LiCor Odyssey Infrared Scanning
instrument. Under the same assay conditions, all enzymes were
verified in fluorogenic assays to be active in processing their specific
tetrapeptide-AMC substrates (data not shown).
The biochemical cleavage assay of lamin A with increasing
concentrations of human active caspase-6 (as indicated) was done in
40 mM HEPES (pH 7.2), 100 mM NaCl, 0.1% CHAPS, 80 mM
DTT for 2 hours at 37uC. The samples were processed as described
above and the signal was quantified using Odyssey software.
Caspase-6 Knockout Mouse
The construct for targeting the C57BL/6 caspase-6 locus in ES
cells was made using a combination of recombineering [33,34] as
well as standard molecular cloning techniques.
Briefly, a 6537 bp fragment (assembly NCBI37/mm9,
chr3:129,606,653-129,613,189) from a C57BL/6 mouse BAC
(RP23-233B14) was first retrieved into plasmid pBlight-TK [34].
Second a loxP-em7-kanamycin-loxP cassette was inserted upstream
of exon 2 between position chr3:129,608,133 and129,608,134.
Correctly targeted plasmid was transformed into arabinose-induced
SW106 cells (Cre expressing E.coli, [35,36]) to remove kanamycin
and leave behind a single loxP site. Finally, an frt-PGK-em7-Neo-
BGHpA-frt-loxP cassette was inserted downstream of exon 4
between position chr3:129,609,697 and 129,609,698, resulting in
the caspase-6 conditional knock-out (CKO) targeting vector. The
final vector was confirmed by DNA sequencing.
The caspase-6 CKO vector was linearized with NotI and
C57BL/6 C2 ES cells were targeted using standard methods
(G418 positive and gancyclovir negative selection). Positive clones
were identified using PCR and taqman analysis, and confirmed by
sequencing of the modified locus. Correctly targeted ES cells were
transfected with a Flpe plasmid to remove Neo and create the
caspase-6 conditional knock-out allele (CKO), or with a Cre
plasmid to remove Neo and create the caspase-6 KO allele.
Caspase-6 KO or CKO ES cells were then injected into
blastocysts using standard techniques, and germline transmission
was obtained after crossing resulting chimaeras with C57BL/6N
females.
Data Analysis
The endpoint absorbance, fluorescent (RFU) or luminescent
(RLU) emission in each well was plotted as a function of inhibitor
concentration and the 50% inhibition (IC50) values were
determined using a nonlinear least squares fit of the data to a
four parameter equation using Prism 5.0 software (GraphPad
Software, San Diego, CA).
Caspase-GloH 6 Assay
SKNAS cells were plated at a density of 20,000 cells per well
into 384-well black clear-bottom cell culture plates in 20 ml/well
growth medium and allowed to adhere overnight. The following
day, 5 ml of peptide inhibitor diluted in growth medium was
delivered to each well 30 minutes prior to addition of 5 ml/well
staurosporine in growth medium. The final DMSO concentration
in the assay was 0.1% and the final staurosporine concentration
was 3 mM. Following 6 hours incubation at 37uC, Caspase-GloH 6
reagents (Promega; Madison, WI) were prepared according to
manufacturer’s recommendation, and 30 ml was added directly to
each well, followed by 1 hour incubation at 37uC and
luminescence recording using a Perkin Elmer Envision.
LDH Release Assay
SKNAS cells were plated at a density of 20,000 cells per well
into 384-well black clear-bottom cell culture plates in 20 ml/well
growth medium and allowed to adhere overnight. The following
day, 5 ml staurosporine diluted in growth medium was delivered to
each well and incubated for the indicated time in a cell culture
incubator. The final DMSO concentration in the assay was 0.1%.
At each timepoint, lactate dehydrogenase (LDH) activity was
measured in cell supernatants using a colorimetric LDH activity
measurement kit (BioVision; Mountain View, CA) according to
manufacturer’s recommendation by measuring absorbance at
450 nm using a Spectramax platereader (Molecular Devices;
Sunnyvale, CA).
Mass Spectrometry Analysis of Intracellular Inhibitor
Accumulation
SKNAS cells were seeded in 12-well plates at a concentration of
5610
6 cells/mL and allowed to adhere overnight prior to the
experiment. Caspase inhibitors (10 mM) in Hank’s balance Salt
Solution (HBSS; Invitrogen) buffer containing 10 mM HEPES
(Invitrogen) and a final DMSO concentration of 0.1% were added
in triplicate to the cells. Non specific binding (NSB) samples were
prepared by immediately aspirating the dose solution and washing
the cells with 1 mL of ice cold HBSS. Cells for the accumulation
experiment were incubated for 1 hour at 37uC with inhibitors
prior to washing with 1 mL ice cold HBSS. Analytical internal
standard (200 nM propranolol (Sigma) in 100% acetonitrile (ACN)
with 0.1% formic acid) and blank HBSS buffer were sequentially
added to the 12-well plates containing the NSB and accumulation
samples. Reference samples for each inhibitor were made by
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hour at 37uC. The cells from all experiments were scraped from
the bottom of the 12 well plates, sonicated for approximately
30 minutes, and centrifuged for 10 minutes at 3000 x g prior to
LC/MS/MS analysis.
The LC/MS/MS system consisted of an AB Sciex API4000
mass spectrometer (AB Sciex, Foster City, CA), an Aria LX2
multiplexing LC system (Thermo Fisher Scientific, Waltham, MA)
and a CTC Analytics autosampler (Leap Technologies, Carrboro,
NC). An ESI Spray source in the positive ion mode and multiple
reaction monitoring (MRM) were used to quantitate peak areas.
The LC separations were performed on a 5062.0 mm Gemini
C18 analytical column (Phenomenex, Torrance, CA). The mobile
phases consisted of water with 0.1% formic acid (mobile phase A)
and ACN with 0.1% formic acid (mobile phase B). Mass
spectrometer data were processed using Analyst software version
1.4.2.
Results
Peptide based inhibitors and substrates lack isoform
selectivity
There are a wide number of commercially available pharma-
cologic reagents that can be used to inhibit the enzymatic activity
of recombinant caspases. Most of these tools are peptide inhibitors
based on preferred substrate recognition sequences that possess an
electrophilic warhead coupled to the P1 Aspartic acid residue for
direct interaction with the enzyme’s catalytic cysteine. For
example, VEID-aldehyde (Ac-VEID-CHO) is generally inferred
as selectively inhibiting caspase-6 while Ac-DEVD-CHO is
considered a caspase-3/7 inhibitor. In order to elucidate the
ability of these tools to dissect executioner caspase activity in a
cellular context, a panel of peptide based caspase inhibitors with
divergent amino sequences and warheads was tested for their
ability to inhibit the enzymatic activity of caspase-3, -6 and -7
(Table 1). Under the assay conditions tested, aldehyde-containing
peptide inhibitors were the most potent against caspase-6 (relative
to fluoro-methyl ketone (FMK) derived inhibitors), but the amino
acid sequence appears to confer little selectivity. For example, Ac-
DEVD-CHO (IC50=30.5 nM) and Ac-IETD-CHO (IC50=53.2
nM), which are canonically considered selective for caspase-3 and
caspase-8, respectively, inhibited caspase-6 with near equal
potency as did Ac-VEID-CHO (IC50=16.2 nM). This lack of
selective inhibition by these tools was seen for each of the
executioner caspases tested (Table 1). As an extension to this
notion, we monitored the proteolysis of a distinct fluorescent
substrate with a VEID recognition motif ((Ac-VEID)2-Rh110) by
each of the three executioner caspases. This substrate was readily
cleaved under initial rate conditions by caspase-3 and -7 with
efficiency comparable to caspase-6 (data not shown) confirming
previous findings with similar peptide substrates [17,18]. This
illustrates the limitation with using any of these reagents as tools to
selectivity monitor caspase-6 activity in a cellular context where
other executioner caspases are present.
Lamin processing by caspase-6
Due to the lack of selectivity of peptide reagents listed above, we
sought to identify a full length substrate that might offer a higher
degree of selective processing. The nuclear envelope proteins
lamin A and lamin C have previously been identified as substrates
for caspase-6 and contain the consensus VEID sequence in a
helical rod section between N and C terminal globular domains.
These two proteins are encoded by a single primary transcript and
therefore share the identical first 566 amino acids with the only
differences occurring in the C-terminus [37]. The efficiency of
purified active caspase-6 to process recombinant lamin A was
evaluated by monitoring its degradation over a range of enzyme
concentrations (Figure 1A). Lamin degradation is evident with as
little as 6 nM caspase-6 (30 U).
To assess proteolytic specificity, the capacity of other caspase
isoforms to degrade recombinant lamin A was evaluated. Western
blot analysis of the reaction products from 300 U active caspases
1–9 reveals that only caspase-6 produced a prominent signal for
cleaved lamin (Figure 1B). It was observed that at higher caspase-3
concentrations (.1000 U) slight lamin processing does occur (data
not shown), although these enzyme conditions are non-catalytic.
Each enzyme was separately evaluated in independent enzymatic
experiments to ensure proficient activity and found to possess
suitable activity and proper pharmacology (data not shown).
Table 1. Potency of peptide-derived caspase inhibitors
possessing aldehyde (CHO) and fluoromethyl ketone (FMK)
warheads against executioner caspases.
Mean IC50* (nM)
Sample Caspase-6 Caspase-3 Caspase-7
Ac-VEID-CHO 16.2 13.6 162.1
Ac-DEVD-CHO 30.5 1.3 3.7
Ac-IETD-CHO 53.2 75.8 552.8
z-VEID-FMK 128.6 45.1 648.0
z-DEVD-FMK 402.3 35.8 98.5
z-VAD-FMK 2112 168.0 74.7
*IC50 values were determined after a 15 minute enzyme/inhibitor preincubation
and 40 minute enzyme reaction. Due to the capacity for time-dependent
inhibition with irreversible inhibitors the values reported can be considered
‘‘apparent IC50’’.
doi:10.1371/journal.pone.0030376.t001
Figure 1. Western blot detection of recombinant GST-lamin A
processing by purified caspases. (A) The indicated concentration of
caspase-6 was incubated with GST-lamin A for two hours. (B) 300 Units
of caspases 1–9 were incubated with GST-lamin A for two hours. Intact
and cleaved lamin A were detected via western blotting using anti-GST
antibody.
doi:10.1371/journal.pone.0030376.g001
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The high degree of selective lamin proteolysis by recombinant
caspase-6 prompted us to investigate the use of this substrate as a
cellular readout for caspase-6 activity. Staurosporine is a non-
selective protein kinase inhibitor that activates caspase-6 [38],
amongst other caspases, in cells as they progress towards apoptosis.
Cell lysates were prepared from SKNAS cells treated with DMSO
or 3 mM staurosporine for six hours to activate the caspase
machinery. The SKNAS cell line is of human neuroblastoma
origin, and was selected for these and following studies due to its
robust caspase induction as assessed using Caspase-GloH 6 assay
kit from Promega as well as by observing zymogen conversion to
active caspase-6 by western blot detection (data not shown). A
panel of three antibodies that bind intact lamin or its proteolytic
fragments were monitored for their ability to detect each lamin A/
C species via western blot (Figure 2A and 2B). All three antibody
preparations detected intact lamin A/C (Lane 5) or its large (Lane
4) or small (Lane 2) proteolytic fragments. As seen in lane 6, the
intact lamin A/C antibody also detects the small proteolytic
fragment produced upon staurosporine treatment suggesting its
binding epitope is on the N-terminus of the protein. On the other
hand, the antibodies against the large or small subunit recognize
neo-epitopes only exposed subsequent to caspase-6 proteolysis and
do not detect intact lamin A/C (Lanes 1, 3). The kinetics of lamin
A/C degradation were monitored by inducing an apoptotic state
with 3 mM staurosporine for 1–6 hours and identified the
abundant appearance of proteolytic fragments after 4–6 hours of
staurosporine treatment (Figure 2C). Induction of cellular caspase
activity with 6 hours of staurosporine treatment was also observed
using the Caspase-GloH 6 assay kit (data not shown) and provided
confidence that this time point was suitable for the remainder of
our assay development.
In order to develop an assay more amenable to inhibitor
screening, this antibody detection was adapted to a plate-based
non-denaturing assay. SKNAS cells cultured in 384-well plates
were treated with 3 mM staurosporine for six hours prior to
Figure 2. Western blot detection of lamin A/C from SKNAS neuroblastoma cells upon staurosporine treatment. (A) Schematic of the N-
and C-terminal globular domains of Lamin A/C with VEID-containing central a-helical region as the site of caspase-6 proteolysis. (B) SKNAS cells were
treated with DMSO control or staurosporine for 6 hours prior to cell lysis. Lysates were probed for small lamin A/C subunit (Lanes 1–2), large lamin A/
C subunit (Lanes 3–4) or total lamin A/C (Lanes 5–6). (C) SKNAS cells were treated with DMSO or staurosporine for the indicated time prior to cell lysis.
Lysates were probed for large lamin A/C subunit (red) or b-Actin (green).
doi:10.1371/journal.pone.0030376.g002
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0.2% Triton X-100. Binding of the two antibodies that recognize
neo-epitopes on the large or small lamin degradation products was
detected by horseradish-peroxidase-labeled secondary antibody
and subsequent chemiluminescent substrate addition (see methods
for details). In this context, the large subunit antibody was unable
to produce a signal window (data not shown), while the small
subunit antibody generated a robust signal and was utilized for
further studies. The concentration dependence of staurosporine
required to evoke lamin A/C degradation after a six-hour
treatment period indicated that 3 mM staurosporine produced a
marked signal:background ratio of 8.8-fold and that higher
concentrations could be used to induce a greater response if
desired (Figure 3). Under these conditions the assay proved highly
robust (Z’$0.7).
This lamin degradation plate-based assay was used to further
investigate the specificity of lamin A/C as a caspase-6 substrate in
a cellular environment. Murine embryonic fibroblast cultures were
established from tail-tissue-explants derived from caspase-6
knockout and wild-type mice and subjected to increasing
concentrations of staurosporine prior to detection of cleaved
lamin (Figure 4). The marked response in the wild-type cells
compared to the caspase-6 knockout cells supports the biochemical
evidence that caspase-6 is the primary caspase responsible for
lamin processing, although emergence of lamin degradation
products begin to appear slightly at the highest staurosporine
concentration tested in the caspase-6 KO fibroblast cells. Under
these conditions, the morphological features associated with
apoptosis were equally observed in both the wild type and KO
cells (data not shown) as would be expected given the ability of
staurosporine to function as a universal apoptotic trigger with
known capacity to activate the caspase-3 machinery [27,39].
Membrane integrity is not compromised during caspase
activation
The goal of the cell-based assay is to measure inhibition of the
intracellular caspase-6 by cell-permeant inhibitors, therefore it is
important to establish that cell membrane integrity has not been
compromised during caspase activation. To assess the integrity of
the SKNAS cell membrane under the staurosporine-induced
apoptotic conditions, lactate dehydrogenase (LDH) release was
measured upon treatment of cells with a range of staurosporine
concentrations and after several incubation time periods. As seen
in Figure 5, the concentration dependent release of LDH in these
cells is also highly dependent on the incubation time. After 6 hours
of treatment, LDH release is detected above background levels
with ,4 mM staurosporine. The same degree of measured LDH
release with 30 mM staurosporine only requires 4 hours of
treatment. These data also illustrate that under conditions in
which maximal lamin cleavage was obtained by wild type but not
caspase-6 KO fibroblasts, cytotoxicity as measured by LDH
release was minimal. This information can facilitate the selection
by the user of incubation time and staurosporine concentration to
develop their preferred assay.
Figure 3. Effect of staurosporine on the generation of cleaved
lamin A/C in SKNAS cells. SKNAS cells were treated with the
indicated concentration of staurosporine for 6 hours prior to detection
of the small lamin A/C cleavage product as described in Experimental
Procedures. The assay was performed in triplicate one time. The mean
and standard error of the mean are reported.
doi:10.1371/journal.pone.0030376.g003
Figure 4. Apoptosis-mediated cleavage of lamin A/C is
elevated in wild-type relative to caspase-6 KO fibroblasts.
Fibroblasts derived from caspase-6 KO (&) or wild type (N) mice were
treated with the indicated concentration of staurosporine for 6 hours
prior to detection of the small lamin A/C cleavage product. The assay
was performed in quadruplicate two times with similar results; mean
and standard error of the mean are reported.
doi:10.1371/journal.pone.0030376.g004
Figure 5. Effect of staurosporine on the release of Lactate
Dehydrogenase in SKNAS cells. SKNAS cells were treated with the
indicated concentration of staurosporine for 2 (N), 4 (&), 6 (m)o r8( ¤)
hours prior to detection of LDH release to the cell supernatant. The
assay was performed in triplicate and represents 1 of at least 2
experiments with similar results. The data was normalized to fold
increase over DMSO treatment. The mean and standard error of the
mean are reported.
doi:10.1371/journal.pone.0030376.g005
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The plate-based version of the lamin degradation assay was
used to monitor the potency of a panel of peptide inhibitors for
their capacity to prevent caspase-6-dependent proteolysis. At
inhibitor concentrations up to 100 mM, little or no inhibitory
activity was observed with the aldehyde or FMK based
tetrapeptide inhibitors possessing a Glu at the second position
despite having submicromolar biochemical potencies (Figure 6A
and data not shown). The nonselective inhibitor z-VAD-FMK
inhibited with 44 mM potency consistent with previously published
reports [40]. This result might be expected given the highly
charged nature of these Glu-containing molecules which prevents
their cellular accumulation. Conversely, the pan caspase inhibitor
Q-VD-OPh, which possesses a difluorophenoxymethyl warhead,
inhibited generation of the small lamin subunit with an IC50 of 940
nM (6-fold lower potency than enzymatic assay) (Figure 6A,
Table 2). To this end, three further peptide inhibitors were
synthesized each with a similar warhead (tetrafluorophenoxy-
methyl (TFPM)) with the attempt to facilitate cell activity (Figure
S1). These new inhibitors are based off the z-VEID recognition
motif and are successively truncated at the N-terminus (z-VEID-
TFPM, z-EID-TFPM, z-ID-TFPM). In biochemical caspase-6
assays, each truncation results in a decrease in potency (1.7nM,
8.4nM, 19nM), while the opposite is seen in the cellular assay
(Figure 6B, Table 2). In this case, the shortest and least charged
inhibitor z-ID-TFPM inhibited lamin degradation most potently
with an IC50=180nM (,10-fold less potent than enzymatic
inhibition). In order to confirm our hypothesis that lack of cellular
activity of these inhibitors is due to their poor membrane
permeability, we analyzed the degree of their SKNAS cellular
accumulation via mass spectrometry. This analysis revealed that
cellular potency is highly correlative with cell penetrance. Q-VD-
OPh and z-ID-TFPM were quantified as the two inhibitors most
readily able to penetrate into cells and also the two most effective
at inhibiting lamin degradation (Table 2). Ac-VEID-CHO is
predominantly excluded from accessing the intracellular environ-
ment (0.16% cellular accumulation) and lacks any activity in the
cellular assay. When the membrane barrier is removed as in the
case of the lysate based Caspase-GloH 6 assay, this peptide
inhibitor as well as Ac-DEVD-CHO (also inactive in lamin
degradation assay) are both clearly able to inhibit VEIDase activity
(Ac-VEID-CHO IC50=0.49mM; Ac-DEVD-CHO IC50=1.49mM)
(Figure 7). It is evident from these data that inhibition in the lamin
degradation assay is dictated by a compound’s absolute binding affinity
and its ability to access the intracellular target.
Discussion
Caspase-6 is an important drug target that is implicated in
various neurodegenerative diseases, yet the availability of tools to
monitor caspase-6 activity in a cellular context is limited. Lysate
based assays such as the Caspase-GloH 6 kit from Promega
function as useful tools to monitor general caspase activity but the
value of this assay as a tool for drug discovery to assess inhibitor
permeability into cells is diminished because of the required lysis
step. Additionally, peptide substrates of this type have been shown
to be readily processed by multiple caspase isoforms and may not
offer the desired specificity to support drug discovery [18].
Furthermore, peptide inhibitors lack the required selectivity profile
to shut down specific branches of the caspase signaling cascade
that is activated in an apoptotic setting [22]. Given the limitations
of these tools, we developed a cellular assay to monitor caspase-6
activity by detecting the proteolytic digestion of a specific
substrate, lamin A/C to allow interrogation of selective caspase-
6 inhibitors.
Lamin A/C is processed by caspase-6 after Asp230 to generate
small and large proteolytic digestion products. We utilized the
availability of antibodies that recognize neo epitopes accessible
only upon cleavage to develop an ELISA assay to monitor
generation of the 25 KDa small lamin product. In order to activate
the caspase machinery we took advantage of the largely cytotoxic
effect of staurosporine on SKNAS neuroblastoma cells to invoke
an apoptotic state. The time and concentration dependent
induction of lamin degradation and LDH release by staurosporine
illustrated within this manuscript provide a detailed indication of
the state of cell health as well as a framework for optimization of
assay parameters required by other investigators. The assay itself
proved very robust with a capacity to support large scale chemistry
efforts directed against caspase-6. The strong assay window is
Figure 6. Effect of peptide-based caspase inhibitors on the
generation of cleaved lamin A/C in SKNAS cells. (A) SKNAS cells
were treated with z-VEID-FMK (¤), z-DEVD-FMK (&), Q-VD-OPh (N), Ac-
VEID-CHO (m)o rA c - D E V D - C H O( #) prior to addition of 3 mM
staurosporine for 6 hours. (B) SKNAS cells were treated with z-ID-TFPM
(N), z-EID-TFPM (m) or z-VEID-TFPM (&) prior to addition of 3 mM
staurosporine for 6 hours. Detection of the small lamin A/C cleavage
product was performed as described in Experimental Procedures.
Concentration inhibition curves were performed in duplicate and
represent 1 of at least 3 experiments with similar results. Concentration-
response curves for each inhibitor were normalized to zero and 100%
based on no staurosporine or DMSO, respectively. The mean and
standard error of the mean are reported.
doi:10.1371/journal.pone.0030376.g006
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any product formation in the absence of staurosporine treatment
combined with signal amplification conferred by the ELISA assay
platform.
In order to confirm the validity of this assay as a useful tool to
interrogate cellular caspase-6 activity, we performed a series of
experiments to address the concern of selectivity. Only purified
caspase-6 was able to effectively proteolyze recombinant lamin A
compared to the extensive panel of caspase isoforms tested. It is
likely that the VEID consensus motif presented in the context of a
full-length protein is able to confer a degree of specificity not
afforded with peptide substrates. It is also possible that secondary
interactions outside the consensus site contribute to its specificity.
Furthermore, lamin A/C degradation was markedly reduced in
fibroblasts extracted from caspase-6 knock-out mice relative to
fibroblasts from wild type mice. The source of the small amount of
remaining lamin A/C cleavage in these KO fibroblasts at the
highest staurosporine concentration might represent crossreactiv-
ity of other caspase isoforms, particulary given the fidelity of
caspase-3 and caspase-7 for their ability to process VEID
containing substrates, or perhaps unrelated proteases capable of
cleaving this protein such as Granzyme A [41]. It is evident from
the KO data combined with biochemical specificity data, however,
that cleavage of lamin A/C is a sound strategy as a readout for
caspase-6 activity in cells.
This assay was pharmacologically evaluated by profiling a panel
of peptide inhibitors for their ability to prevent lamin A/C
degradation. Surprisingly, only inhibitors with warheads capable
of covalent cysteine modification (fluoromethylketone, difluoro-
phenoxymethyl and tetrafluorophenoxymethyl) were able to
prevent the cleavage of lamin A/C while aldehyde-based
inhibitors lacked cell activity. Although this analysis is confused
by the low permeability of the aldehyde inhibitors, this observation
might provide suggestive evidence that covalent modification of
caspase-6 is a prerequisite for in vivo efficacy. Extensive
experimentation beyond the scope of this manuscript is required
to completely address this notion. The strong disconnect between
cellular and biochemical potency for many of the inhibitors was
easily rationalized by measuring the intracellular accumulation of
the peptides whose highly charged nature might contribute to cell
exclusion. These data serve to assist in the pharmacological
validation of this assay as well as provide direct evidence that
despite cells existing in an apoptotic state, they maintain cell
membrane integrity. Overall, the assay will aid in the discovery of
selective caspase-6 inhibitors with reasonable physiochemical
properties.
In summary, we report here a whole-cell high throughput 384-
well assay which monitors cellular caspase-6 cleavage of
endogenous lamin A/C under apoptotic conditions. The assay is
performed in a physiologically relevant cell line without the
necessity of genetic engineering and is able to discriminate against
chemical compounds with poor membrane penetrance. This assay
is the first reported to monitor caspase-6 activity in the context of
mammalian cells and the capacity of the antibody to react across
multiple species enhances the versatility of this technique for
adaptation to a variety of cell backgrounds. With recent data
Table 2. Comparison of potency of peptide-derived caspase inhibitors in cellular lamin cleavage assay, enzymatic activity and cell
permeability.
Sample
Cellular Lamin Cleavage
IC50 (mM) Enzymatic Caspase-6 IC50*(mM) % cell accumulation
Ac-VEID-CHO .100 0.016 0.16
Ac-DEVD-CHO .100 0.031 Nd
z-VEID-FMK 45 0.129 0.46
z-DEVD-FMK .100 0.402 nd
z-VAD-FMK 44 2.11 nd
Q-VD-OPh 0.94 0.156 1.72
z-VEID-TFPM 12 ,0.0017
a 0.17
z-EID-TFPM 21 0.0084 nd
z-ID-TFPM 0.18 0.019 1.97
nd=not determined.
a=z-VEID-TFPM enzymatic IC50 is less than 0.0017 due to limit of enzymatic assay detection.
*Enzymatic IC50 values were determined after a 15 minute enzyme/inhibitor preincubation and 40 minute enzyme reaction.
doi:10.1371/journal.pone.0030376.t002
Figure 7. Effect of peptide-based caspase inhibitors on SKNAS
cells as determined using the Caspase-GloH 6 assay. SKNAS cells
were treated with Ac-VEID-CHO (N) or Ac-DEVD-CHO (&) prior to
addition of 3 mM staurosporine for 6 hours and detection of VEID-ase
activity as described in Experimental Procedures. Concentration
inhibition curves were performed in duplicate and represent 1 of at
least 3 experiments with similar results. Concentration-response curves
for each inhibitor were normalized to zero and 100% based on no
staurosporine or DMSO, respectively. The mean and standard error of
the mean are reported.
doi:10.1371/journal.pone.0030376.g007
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ative diseases, the assay described here enables drug discovery
efforts to characterize cell-active inhibitors of this target.
Supporting Information
Figure S1 Chemical structures of peptide inhibitors possessing
aldehyde (CHO), Fluoromethyl Ketone (FMK), Difluorophenox-
ymethyl (OPh) or Tetrafluorophenoxymethyl (TFPM) warheads.
(TIF)
Acknowledgments
We thank Soren Warming, Merone Roose-Girma and Anatoly Nikolaev
for generating the caspase-6 KO mice. We also thank Mike Elliott,
Jiansheng Wu, Hong Li and Yvonne Franke for expressing and purifying
recombinant caspases.
Author Contributions
Conceived and designed the experiments: RM SR RNH CEH. Performed
the experiments: RM SR KS RNH EP. Analyzed the data: RM SR RNH
CEH. Contributed reagents/materials/analysis tools: CDP XZ FC JWL.
Wrote the paper: RM CEH.
References
1. Earnshaw WC, Martins LM, Kaufmann SH (1999) Mammalian caspases:
structure, activation, substrates, and functions during apoptosis. Annu Rev
Biochem 68: 383–424.
2. Albrecht S, Bourdeau M, Bennett D, Mufson EJ, Bhattacharjee M, et al. (2007)
Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol
170: 1200–1209.
3. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, et al. (2004) Active
caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and
neurofibrillary tangles of Alzheimer’s disease. Am J Pathol 165: 523–531.
4. Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena R,
et al. (2008) Accumulation of aspartic acid421- and glutamic acid391-cleaved tau
in neurofibrillary tangles correlates with progression in Alzheimer disease.
J Neuropathol Exp Neurol 67: 470–483.
5. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, et al. (1999)
Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid-beta
precursor protein and amyloidogenic A beta peptide formation. Cell 97:
395–406.
6. Nikolaev A, McLaughlin T, O’Leary DD, Tessier-Lavigne M (2009) APP binds
DR6 to trigger axon pruning and neuron death via distinct caspases. Nature
457: 981–989.
7. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. (2006) Cleavage at the
caspase-6 site is required for neuronal dysfunction and degeneration due to
mutant huntingtin. Cell 125: 1179–1191.
8. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, et al. (2004) Specific
caspase interactions and amplification are involved in selective neuronal
vulnerability in Huntington’s disease. Cell Death Differ 11: 424–438.
9. Leyva MJ, Degiacomo F, Kaltenbach LS, Holcomb J, Zhang N, et al. (2010)
Identification and evaluation of small molecule pan-caspase inhibitors in
Huntington’s disease models. Chem Biol 17: 1189–1200.
10. Giaime E, Sunyach C, Druon C, Scarzello S, Robert G, et al. (2009) Loss of
function of DJ-1 triggered by Parkinson’s disease-associated mutation is due to
proteolytic resistance to caspase-6. Cell Death Differ 17: 158–169.
11. Boatright KM, Salvesen GS (2003) Mechanisms of caspase activation. Curr
Opin Cell Biol 15: 725–731.
12. Salvesen GS, Dixit VM (1999) Caspase activation: the induced-proximity model.
Proc Natl Acad Sci U S A 96: 10964–10967.
13. Wang XJ, Cao Q, Liu X, Wang KT, Mi W, et al. (2010) Crystal structures of
human caspase 6 reveal a new mechanism for intramolecular cleavage self-
activation. EMBO Rep 11: 841–847.
14. Timmer JC, Salvesen GS (2007) Caspase substrates. Cell Death Differ 14:
66–72.
15. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, et al. (1997)
Substrate specificities of caspase family proteases. J Biol Chem 272: 9677–9682.
16. Klaiman G, Petzke TL, Hammond J, Leblanc AC (2008) Targets of caspase-6
activity in human neurons and Alzheimer disease. Mol Cell Proteomics 7:
1541–1555.
17. McStay GP, Salvesen GS, Green DR (2008) Overlapping cleavage motif
selectivity of caspases: implications for analysis of apoptotic pathways. Cell
Death Differ 15: 322–331.
18. Pereira NA, Song Z (2008) Some commonly used caspase substrates and
inhibitors lack the specificity required to monitor individual caspase activity.
Biochem Biophys Res Commun 377: 873–877.
19. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM (1996) The CED-3/
ICE-like protease Mch2 is activated during apoptosis and cleaves the death
substrate lamin A. J Biol Chem 271: 16443–16446.
20. Ruchaud S, Korfali N, Villa P, Kottke TJ, Dingwall C, et al. (2002) Caspase-6
gene disruption reveals a requirement for lamin A cleavage in apoptotic
chromatin condensation. Embo J 21: 1967–1977.
21. Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G,
et al. (1996) Cleavage of lamin A by Mch2 alpha but not CPP32: multiple
interleukin 1 beta-converting enzyme-related proteases with distinct substrate
recognition properties are active in apoptosis. Proc Natl Acad Sci U S A 93:
8395–8400.
22. Berger AB, Sexton KB, Bogyo M (2006) Commonly used caspase inhibitors
designed based on substrate specificity profiles lack selectivity. Cell Res 16:
961–963.
23. Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R (1999) Non-
specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 442:
117–121.
24. Komoriya A, Packard BZ, Brown MJ, Wu ML, Henkart PA (2000) Assessment
of caspase activities in intact apoptotic thymocytes using cell-permeable
fluorogenic caspase substrates. J Exp Med 191: 1819–1828.
25. Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D (2009) An
improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide
for apoptosis imaging. Bioconjug Chem 20: 702–709.
26. Packard BZ, Komoriya A (2008) A method in enzymology for measuring
hydrolytic activities in live cell environments. Methods Enzymol 450: 1–19.
27. Zhang HZ, Kasibhatla S, Guastella J, Tseng B, Drewe J, et al. (2003) N-Ac-
DEVD-N’-(Polyfluorobenzoyl)-R110: novel cell-permeable fluorogenic caspase
substrates for the detection of caspase activity and apoptosis. Bioconjug Chem
14: 458–463.
28. Gray DC, Mahrus S, Wells JA (2010) Activation of specific apoptotic caspases
with an engineered small-molecule-activated protease. Cell 142: 637–646.
29. Figueroa RA, Ramberg V, Gatsinzi T, Samuelsson M, Zhang M, et al. (2011)
Anchored FRET sensors detect local caspase activation prior to neuronal
degeneration. Mol Neurodegener 6: 35.
30. Chang HK, Oh YS, Jang YJ, Kim SS, Min KS, et al. (2008) LG Life Sciences
LTD. Caspase Inhibitors Based on Pyridazinone Scaffold. WO 2008/ 056897.
31. Knegtel R, Mortimore M, Studley J, Millan D (2004) Vertex Pharmaceuticals.
Caspase Inhibitors and Uses Thereof. WO 2004/ 002961.
32. Elliott JM, Rouge L, Wiesmann C, Scheer JM (2009) Crystal structure of
procaspase-1 zymogen domain reveals insight into inflammatory caspase
autoactivation. J Biol Chem 284: 6546–6553.
33. Liu P, Jenkins NA, Copeland NG (2003) A highly efficient recombineering-based
method for generating conditional knockout mutations. Genome Res 13:
476–484.
34. Warming S, Rachel RA, Jenkins NA, Copeland NG (2006) Zfp423 is required
for normal cerebellar development. Mol Cell Biol 26: 6913–6922.
35. Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, et al. (2001) A
highly efficient Escherichia coli-based chromosome engineering system adapted
for recombinogenic targeting and subcloning of BAC DNA. Genomics 73:
56–65.
36. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG (2005) Simple
and highly efficient BAC recombineering using galK selection. Nucleic Acids
Res 33: e36.
37. Mounkes LC, Burke B, Stewart CL (2001) The A-type lamins: nuclear structural
proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends
Cardiovasc Med 11: 280–285.
38. Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, et al. (2008) Activated
caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in
the nucleus. Hum Mol Genet 17: 2390–2404.
39. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, et al. (1999) Role
of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-
resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol
Chem 274: 22932–22940.
40. Fennell M, Chan H, Wood A (2006) Multiparameter measurement of caspase 3
activation and apoptotic cell death in NT2 neuronal precursor cells using high-
content analysis. J Biomol Screen 11: 296–302.
41. Zhang D, Beresford PJ, Greenberg AH, Lieberman J (2001) Granzymes A and B
directly cleave lamins and disrupt the nuclear lamina during granule-mediated
cytolysis. Proc Natl Acad Sci U S A 98: 5746–5751.
Cellular Caspase-6 Activity Assay
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e30376